, /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Shareholders who purchased shares of QDEL during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: to The complaint that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (a) that QuidelOrtho sold more COVID-19 tests to its distributors and pharmacy chain customers than they could resell to healthcare providers and end customers; (b) that excess inventories of COVID-19 tests existed throughout the supply chain; (c) that, as a result of (a)-(b) above, QuidelOrtho's distributors and pharmacy chain customers were poised to significantly reduce their COVID-19 test orders; (d) that undisclosed problems created a heightened risk that the new test called the savanna respiratory viral panel-4 test would experience a delayed commercial launch in the united states; (e) that, as a result of (a)-(d) above, defendants lacked a reasonable basis for their positive statements about QuidelOrtho's business, financials, and growth trajectory.
Shareholders should not delay in registering for this class action. Register your information here: Once you register as a shareholder who purchased shares of QDEL during the timeframe listed above, you will be enrolled in a portfolio monitoring software to pr.
